All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

mianserin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
serotonin receptor antagonists (mostly 5-HT2)	1796	24219-97-4

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: mianserin hydrochloride mianserin mianserine (+/-)-Mianserin mianserine hydrochloride mianserin HCl mianserine HCl	A tetracyclic compound with antidepressant effects. It may cause drowsiness and hematological problems. Its mechanism of therapeutic action is not well understood, although it apparently blocks alpha-adrenergic, histamine H1, and some types of serotonin receptors. Molecular weight: 264.37 Formula: C18H20N2 CLOGP: 4.01 LIPINSKI: 0 HAC: 2 HDO: 0 TPSA: 6.48 ALOGS: -3.06 ROTB: 0

Drug dosage:

Dose	Unit	Route
60	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	3.40 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	5 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	6.48 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	22 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	13.75 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	21.90 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.05 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	9.60 hours	Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
azlogd74	LogD at pH 7.4	3.338		High	1
caco2-efflux	Caco-2 efflux ratio (BA/AB)	0.449		High	1
caco2-intrinsic-papp	Caco-2 intrinsic apparent permeability	33.420	10^-6 cm/s	High	1
dh-clint	Dog hepatocyte intrinsic clearance	43.351	uL/min/10^6 cells	High	1
dppb	Dog plasma protein binding (% unbound)	6.050	%	High	1
fcs-ppb	Fetal calf serum protein binding (% unbound)	9.900	%	High	1
herg	hERG pIC50	5.510	pIC50	High	1
hh-clint	Human hepatocyte intrinsic clearance	10.233	uL/min/10^6 cells	High	1
hlm-clint	Human liver microsomal intrinsic clearance	46.452	uL/min/mg protein	High	1
hppb	Human plasma protein binding (% unbound)	4.910	%	High	1
kinase-safety-class	ACVR2A,ACVR2B,AKT2,AKT3,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,JAK2,JAK3,MAP3K7,MAPK10,MAPK7,MAPKAPK2,MET,NTRK2,PDK4,PDPK1,PIM2,PRKDC,SIK2,STK33,TEK,TGFBR1	34
kinase-selectivity-class	AXL,PDK4	2
mdck-mdr1-efflux	MDCK-MDR1 efflux ratio	0.247		High	1
mh-clint	Mouse hepatocyte intrinsic clearance	200.447		High	1
mppb	Mouse plasma protein binding (% unbound)	6.810		High	1
nih-mdck-mdr1-efflux	NIH MDCK-MDR1 efflux ratio	0.509		High	1
pfas-class	PFAS structural alert (1 = True, 0 = False)	0
pld-class	Phospholipidosis risk class (1 = positive, 0 = negative)	1		High	1
pppb	Pig plasma protein binding (% unbound)	16.670	%	High	1
rh-clint	Rat hepatocyte intrinsic clearance	259.418	uL/min/10^6 cells	High	1
rh-fuinc	Rat hepatocyte fraction unbound in incubation	25.310	%	High	1
rppb	Rat plasma protein binding (% unbound)	7.880	%	High	1
solubility-dd	Solubility at pH 7.4 in DMSO	313.329	uM	High	1

Approvals:

Date	Agency	Company	Orphan
Jan. 1, 1976	YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Coma	277.93	31.77	126	6581	72506	90549234
Hyponatraemia	208.20	31.77	127	6580	133411	90488329
Camptocormia	179.84	31.77	29	6678	264	90621476
Drug interaction	162.56	31.77	146	6561	276307	90345433
Poisoning deliberate	159.73	31.77	56	6651	16430	90605310
Toxicity to various agents	159.44	31.77	147	6560	287699	90334041
Pleurothotonus	158.95	31.77	33	6674	1302	90620438
Fall	156.93	31.77	185	6522	481625	90140115
Agranulocytosis	150.59	31.77	66	6641	34936	90586804
Hepatocellular injury	132.38	31.77	57	6650	28901	90592839
Somnolence	129.87	31.77	114	6593	208970	90412770
Cholestasis	120.04	31.77	57	6650	36242	90585498
Acute kidney injury	119.22	31.77	132	6575	320255	90301485
Altered state of consciousness	108.82	31.77	51	6656	31481	90590259
Drug reaction with eosinophilia and systemic symptoms	99.72	31.77	53	6654	42705	90579035
Bradycardia	98.90	31.77	67	6640	83780	90537960
Bradypnoea	86.80	31.77	26	6681	4632	90617108
Drug abuse	85.84	31.77	61	6646	82286	90539454
Thymus disorder	74.96	31.77	14	6693	316	90621424
Extrapyramidal disorder	70.91	31.77	31	6676	16272	90605468
Wrong patient received product	63.02	31.77	19	6688	3458	90618282
Vertigo	62.07	31.77	47	6660	69764	90551976
Miosis	61.51	31.77	24	6683	9460	90612280
Sedation complication	60.27	31.77	28	6679	16916	90604824
Blood lactic acid	53.31	31.77	9	6698	111	90621629
Housebound	53.11	31.77	10	6697	236	90621504
Suicide attempt	48.46	31.77	42	6665	75357	90546383
Brain death	48.07	31.77	16	6691	4005	90617735
Rash	47.22	31.77	3	6704	796097	89825643
Hepatic cytolysis	46.99	31.77	29	6678	30887	90590853
Traumatic haematoma	46.73	31.77	13	6694	1782	90619958
Oesophageal food impaction	45.25	31.77	9	6698	285	90621455
Inappropriate antidiuretic hormone secretion	44.95	31.77	24	6683	19481	90602259
Cutaneous lymphoma	43.25	31.77	8	6699	171	90621569
Parkinsonism	43.16	31.77	21	6686	14044	90607696
Basilar artery occlusion	42.36	31.77	8	6699	192	90621548
Vertebral artery occlusion	42.05	31.77	8	6699	200	90621540
Morbid thoughts	41.95	31.77	10	6697	744	90620996
Suicidal ideation	41.23	31.77	38	6669	73817	90547923
Hypothermia	41.13	31.77	21	6686	15554	90606186
Drug-device interaction	39.76	31.77	7	6700	112	90621628
Rash maculo-papular	39.59	31.77	29	6678	40904	90580836
Limbic encephalitis	39.26	31.77	8	6699	287	90621453
Eosinophilia	38.94	31.77	25	6682	28508	90593232
Oesophageal achalasia	37.89	31.77	9	6698	659	90621081
Confusional state	37.57	31.77	86	6621	386119	90235621
Respiratory acidosis	37.13	31.77	16	6691	8103	90613637
Hypotension	36.79	31.77	77	6630	325320	90296420
Disturbance in attention	35.97	31.77	29	6678	47080	90574660
Pulmonary embolism	35.47	31.77	46	6661	130774	90490966
Hyperkalaemia	35.44	31.77	33	6674	64931	90556809
Hepatitis	34.91	31.77	34	6673	70705	90551035
Arthralgia	34.01	31.77	8	6699	778514	89843226
Exposure via transplant	33.60	31.77	5	6702	25	90621715
Foetal alcohol syndrome	33.13	31.77	5	6702	28	90621712
Pneumonia aspiration	32.96	31.77	26	6681	40914	90580826
Gamma-glutamyltransferase increased	32.50	31.77	25	6682	37927	90583813

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cerebral artery thrombosis	148.00	27.94	34	5502	1215	42614584
Brain scan abnormal	137.61	27.94	32	5504	1207	42614592
Coma	120.39	27.94	79	5457	53475	42562324
Areflexia	102.56	27.94	32	5504	3711	42612088
Somnolence	95.54	27.94	104	5432	141001	42474798
Ischaemic stroke	81.63	27.94	45	5491	22188	42593611
Poisoning deliberate	81.24	27.94	35	5501	10099	42605700
Hemiplegia	79.27	27.94	32	5504	7847	42607952
Drug interaction	72.00	27.94	126	5410	266873	42348926
Respiratory distress	68.84	27.94	51	5485	41769	42574030
Drug abuse	68.69	27.94	76	5460	104695	42511104
Facial paralysis	64.95	27.94	32	5504	12531	42603268
Hepatocellular injury	63.26	27.94	39	5497	23639	42592160
Hepatic cytolysis	49.30	27.94	35	5501	26809	42588990
Altered state of consciousness	48.84	27.94	36	5500	29223	42586576
Withdrawal syndrome	46.36	27.94	27	5509	14748	42601051
Reticulocytosis	45.52	27.94	10	5526	290	42615509
Agranulocytosis	45.19	27.94	35	5501	30577	42585222
Painful ejaculation	44.66	27.94	9	5527	170	42615629
Adenomatous polyposis coli	44.41	27.94	9	5527	175	42615624
Poikiloderma	44.40	27.94	10	5526	326	42615473
Dissociative disorder	42.30	27.94	11	5525	661	42615138
Reduced facial expression	41.54	27.94	13	5523	1520	42614279
Wrong patient received product	41.09	27.94	16	5520	3567	42612232
Disease recurrence	39.65	27.94	32	5504	29646	42586153
Cholestasis	38.82	27.94	33	5503	32846	42582953
Gallbladder injury	37.87	27.94	8	5528	192	42615607
Cardio-respiratory arrest	37.43	27.94	42	5494	58594	42557205
Fear	36.97	27.94	21	5515	10944	42604855
Anti-platelet antibody positive	35.22	27.94	8	5528	271	42615528
Coombs direct test positive	33.51	27.94	8	5528	338	42615461
Lichenoid keratosis	32.82	27.94	14	5522	3936	42611863
Initial insomnia	32.55	27.94	14	5522	4016	42611783
Blood bilirubin unconjugated increased	32.52	27.94	9	5527	686	42615113
Pneumonia aspiration	32.18	27.94	36	5500	50042	42565757
Meningioma	32.05	27.94	11	5525	1716	42614083
Haptoglobin decreased	32.01	27.94	9	5527	727	42615072
Drug dependence	31.91	27.94	28	5508	29066	42586733
Blood glucose fluctuation	30.81	27.94	14	5522	4573	42611226
Drug-disease interaction	29.96	27.94	9	5527	917	42614882
Benign soft tissue neoplasm	29.45	27.94	6	5530	120	42615679
Panic attack	28.99	27.94	18	5518	11027	42604772
Painful erection	28.29	27.94	7	5529	344	42615455

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Coma	371.32	24.72	204	12046	117665	110459384
Poisoning deliberate	242.69	24.72	96	12154	26235	110550814
Somnolence	228.28	24.72	218	12032	297231	110279818
Drug interaction	214.92	24.72	270	11980	499913	110077136
Hepatocellular injury	176.90	24.72	94	12156	50548	110526501
Agranulocytosis	175.42	24.72	100	12150	61660	110515389
Camptocormia	153.35	24.72	29	12221	459	110576590
Hyponatraemia	150.81	24.72	151	12099	217502	110359547
Altered state of consciousness	144.30	24.72	86	12164	57540	110519509
Cholestasis	142.88	24.72	89	12161	64429	110512620
Fall	138.75	24.72	243	12007	603239	109973810
Drug abuse	137.67	24.72	131	12119	177280	110399769
Cerebral artery thrombosis	133.17	24.72	32	12218	1636	110575413
Brain scan abnormal	129.87	24.72	31	12219	1540	110575509
Toxicity to various agents	126.96	24.72	206	12044	480349	110096700
Pleurothotonus	120.34	24.72	32	12218	2466	110574583
Acute kidney injury	112.58	24.72	229	12021	635201	109941848
Hepatic cytolysis	97.43	24.72	66	12184	54987	110522062
Wrong patient received product	96.95	24.72	34	12216	6640	110570409
Drug reaction with eosinophilia and systemic symptoms	94.64	24.72	76	12174	82019	110495030
Ischaemic stroke	91.52	24.72	57	12193	41206	110535843
Bradycardia	89.87	24.72	98	12152	155419	110421630
Respiratory distress	88.53	24.72	68	12182	68806	110508243
Areflexia	85.17	24.72	31	12219	6738	110570311
Extrapyramidal disorder	77.26	24.72	45	12205	28822	110548227
Miosis	71.66	24.72	39	12211	21944	110555105
Suicide attempt	68.31	24.72	70	12180	103324	110473725
Bradypnoea	64.13	24.72	27	12223	8622	110568427
Pneumonia aspiration	62.94	24.72	60	12190	81173	110495876
Thymus disorder	61.31	24.72	14	12236	572	110576477
Withdrawal syndrome	58.82	24.72	39	12211	31341	110545708
Arthralgia	55.04	24.72	10	12240	779622	109797427
Vertigo	52.34	24.72	56	12194	86814	110490235
Suicidal ideation	52.15	24.72	58	12192	93879	110483170
Hemiplegia	51.84	24.72	32	12218	22750	110554299
Cardio-respiratory arrest	51.79	24.72	64	12186	115772	110461277
Painful ejaculation	50.54	24.72	9	12241	100	110576949
Confusional state	50.12	24.72	139	12111	468541	110108508
Facial paralysis	50.05	24.72	32	12218	24182	110552867
Sedation complication	48.02	24.72	29	12221	19826	110557223
Hypotension	47.99	24.72	147	12103	523702	110053347
Disturbance in attention	44.65	24.72	44	12206	61951	110515098
Rash	44	24.72	18	12232	820946	109756103
Rash maculo-papular	43.22	24.72	47	12203	74175	110502874
Housebound	42.78	24.72	10	12240	453	110576596
Behaviour disorder	42.63	24.72	21	12229	9626	110567423
Poikiloderma	42.18	24.72	10	12240	482	110576567
Dissociative disorder	41.68	24.72	12	12238	1239	110575810
Traumatic haematoma	41.65	24.72	14	12236	2407	110574642
Adenomatous polyposis coli	40.60	24.72	9	12241	321	110576728
Hypothermia	40.58	24.72	29	12221	26273	110550776
Reticulocytosis	39.57	24.72	10	12240	630	110576419
Gamma-glutamyltransferase increased	39.56	24.72	41	12209	61268	110515781
Drug hypersensitivity	38.93	24.72	3	12247	454087	110122962
Drug dependence	38.84	24.72	37	12213	49983	110527066
Brain death	37.30	24.72	17	12233	6556	110570493
Blood lactic acid	37.28	24.72	9	12241	469	110576580
Pain in extremity	37.16	24.72	5	12245	487113	110089936
Drug-device interaction	36.38	24.72	7	12243	122	110576927
Cutaneous lymphoma	36.29	24.72	8	12242	278	110576771
Headache	36.21	24.72	27	12223	882350	109694699
Morbid thoughts	35.98	24.72	10	12240	909	110576140
Basilar artery occlusion	35.91	24.72	8	12242	292	110576757
Oesophageal food impaction	35.75	24.72	9	12241	558	110576491
Overdose	35.12	24.72	79	12171	233715	110343334
Anti-platelet antibody positive	34.68	24.72	8	12242	342	110576707
Dyspnoea	33.77	24.72	44	12206	1106828	109470221
Fear	32.22	24.72	24	12226	23169	110553880
Painful erection	31.96	24.72	7	12243	236	110576813
Vertebral artery occlusion	31.81	24.72	8	12242	494	110576555
Lichenoid keratosis	31.72	24.72	15	12235	6287	110570762
Exposure via transplant	31.59	24.72	5	12245	25	110577024
Coombs direct test positive	31.33	24.72	8	12242	525	110576524
Parkinsonism	30.91	24.72	23	12227	22164	110554885
Oesophageal achalasia	30.51	24.72	9	12241	1012	110576037
Initial insomnia	29.94	24.72	17	12233	10372	110566677
Benign soft tissue neoplasm	29.90	24.72	6	12244	131	110576918
Disease recurrence	29.46	24.72	35	12215	60749	110516300
Poisoning	29.45	24.72	25	12225	29080	110547969
Blood bilirubin unconjugated increased	29.21	24.72	9	12241	1172	110575877
Peripheral swelling	28.86	24.72	5	12245	404029	110173020
Infusion related reaction	28.86	24.72	4	12246	381158	110195891
Generalised anxiety disorder	28.65	24.72	11	12239	2768	110574281
Hepatitis	28.40	24.72	42	12208	90012	110487037
Rhabdomyolysis	28.15	24.72	49	12201	120352	110456697
Inappropriate antidiuretic hormone secretion	28.12	24.72	26	12224	33825	110543224
Limbic encephalitis	28.04	24.72	8	12242	800	110576249
Single umbilical artery	27.72	24.72	4	12246	9	110577040
Electrocardiogram QT prolonged	27.66	24.72	46	12204	108914	110468135
Pneumonia	27.59	24.72	34	12216	876680	109700369
Hypersensitivity	26.76	24.72	6	12244	403992	110173057
Hallucination, visual	26.47	24.72	27	12223	39578	110537471
Pain	26.09	24.72	41	12209	954914	109622135
Neuroleptic malignant syndrome	26.07	24.72	25	12225	34034	110543015
Blood glucose fluctuation	26.04	24.72	14	12236	7684	110569365
Haptoglobin decreased	25.78	24.72	9	12241	1732	110575317
Reduced facial expression	25.74	24.72	11	12239	3640	110573409
Persecutory delusion	25.74	24.72	13	12237	6278	110570771
Cerebral haematoma	25.72	24.72	15	12235	9617	110567432
Fatigue	25.60	24.72	61	12189	1215897	109361152
Respiratory acidosis	25.46	24.72	17	12233	13809	110563240
Disorientation	25.28	24.72	35	12215	70636	110506413
Drug intolerance	25.06	24.72	7	12243	406505	110170544
Penile pain	25.02	24.72	8	12242	1176	110575873
Drug-disease interaction	24.85	24.72	9	12241	1927	110575122
Frontotemporal dementia	24.77	24.72	7	12243	676	110576373
Infection	24.76	24.72	5	12245	362195	110214854

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N06AX03	NERVOUS SYSTEM PSYCHOANALEPTICS ANTIDEPRESSANTS Other antidepressants
MeSH PA	D000317	Adrenergic alpha-Antagonists
MeSH PA	D000928	Antidepressive Agents
MeSH PA	D006633	Histamine Antagonists
MeSH PA	D006634	Histamine H1 Antagonists
MeSH PA	D011619	Psychotropic Drugs
MeSH PA	D012702	Serotonin Antagonists
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018490	Serotonin Agents
MeSH PA	D018663	Adrenergic Agents
MeSH PA	D018674	Adrenergic Antagonists
MeSH PA	D018687	Antidepressive Agents, Second-Generation
CHEBI has role	CHEBI:176497	geroprotector
CHEBI has role	CHEBI:35469	antidepressant
CHEBI has role	CHEBI:35474	anxiolytic drug
CHEBI has role	CHEBI:35476	antipsychotic agent
CHEBI has role	CHEBI:35640	adrenergic uptake inhibitor
CHEBI has role	CHEBI:35678	histamine agonist
CHEBI has role	CHEBI:35717	sedative
CHEBI has role	CHEBI:37890	α-adrenergic antagonist
CHEBI has role	CHEBI:37955	H<small><sub>1</sub></small>-receptor antagonist
CHEBI has role	CHEBI:48279	serotonergic antagonist
CHEBI has role	CHEBI:76779	EC 3.4.21.26 (prolyl oligopeptidase) inhibitor

Related Drugs by ATC class:

N06AX Other antidepressants 28 drugs

agomelatinebifemelanebrexanolonebupropiondesvenlafaxinedextromethorphanduloxetineesketaminegepironelevomilnacipranmedifoxaminemilnacipran show all 28 →

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Major depressive disorder	indication	370143000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.2	Basic
pKa2	1.03	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN	ANTAGONIST	Ki	8.52		WOMBAT-PK	IUPHAR
5-hydroxytryptamine receptor 2B	GPCR	P41595	5HT2B_HUMAN	ANTAGONIST	Ki	8.12		WOMBAT-PK	IUPHAR
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN	ANTAGONIST	Ki	8.17		WOMBAT-PK	IUPHAR
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN		Ki	8.32		WOMBAT-PK
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN		Ki	5.40		PDSP
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		Kd	7.15		WOMBAT-PK
5-hydroxytryptamine receptor 1A	GPCR	P08908	5HT1A_HUMAN		Ki	6.13		WOMBAT-PK
5-hydroxytryptamine receptor 6	GPCR	P50406	5HT6R_HUMAN		Ki	7.18		WOMBAT-PK
5-hydroxytryptamine receptor 7	GPCR	P34969	5HT7R_HUMAN		Ki	7.06		WOMBAT-PK
Alpha-1A adrenergic receptor	GPCR	P35348	ADA1A_HUMAN		IC50	6.39		CHEMBL
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN		Ki	7.57		WOMBAT-PK
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN		Ki	5.55		CHEMBL
Histamine H1 receptor	GPCR	P35367	HRH1_HUMAN		Ki	9.25		WOMBAT-PK
Histamine H2 receptor	GPCR	P25021	HRH2_HUMAN		Ki	6.00		DRUG MATRIX
Histamine H4 receptor	GPCR	Q9H3N8	HRH4_HUMAN		EC50	6.13		WOMBAT-PK
Muscarinic acetylcholine receptor M1	GPCR	P11229	ACM1_HUMAN		Ki	6.47		DRUG MATRIX
Muscarinic acetylcholine receptor M2	GPCR	P08172	ACM2_HUMAN		Ki	6.42		DRUG MATRIX
Muscarinic acetylcholine receptor M3	GPCR	P20309	ACM3_HUMAN		Ki	6.53		DRUG MATRIX
Muscarinic acetylcholine receptor M4	GPCR	P08173	ACM4_HUMAN		Ki	6.54		DRUG MATRIX
Muscarinic acetylcholine receptor M5	GPCR	P08912	ACM5_HUMAN		Ki	6.64		DRUG MATRIX
5-hydroxytryptamine receptor 1B	GPCR	P28222	5HT1B_HUMAN		Ki	7.53		WOMBAT-PK
5-hydroxytryptamine receptor 1D	GPCR	P28221	5HT1D_HUMAN		Ki	6.99		WOMBAT-PK
Alpha-2C adrenergic receptor	GPCR	P18825	ADA2C_HUMAN		Ki	8.42		WOMBAT-PK
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN		Ki	5.03		PDSP
D(4) dopamine receptor	GPCR	P21917	DRD4_HUMAN		IC50	5.48		CHEMBL
Alpha-1D adrenergic receptor	GPCR	P25100	ADA1D_HUMAN	ANTAGONIST	Ki	7.50		IUPHAR
5-hydroxytryptamine receptor 3A	Ion channel	P46098	5HT3A_HUMAN		Ki	6.21		DRUG MATRIX
Alpha-1B adrenergic receptor	GPCR	P35368	ADA1B_HUMAN	ANTAGONIST	Ki	7.40		IUPHAR
5-hydroxytryptamine receptor 1F	GPCR	P30939	5HT1F_HUMAN		Ki	8.06		WOMBAT-PK
Sodium channel alpha subunits; brain (Types I, II, III)	Ion channel	P35498 Q99250 Q9NY46	SCN1A_HUMAN SCN2A_HUMAN SCN3A_HUMAN		IC50	5.26		CHEMBL
D(1A) dopamine receptor	GPCR	P21728	DRD1_HUMAN		Ki	6		WOMBAT-PK
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN		Ki	5.66		CHEMBL
Alpha-1B adrenergic receptor	GPCR		ADA1B_RAT		Ki	7.18		DRUG MATRIX
5-hydroxytryptamine receptor 1B	GPCR		5HT1B_RAT		Ki	5.33		CHEMBL
Alpha-1A adrenergic receptor	GPCR		ADA1A_RAT		IC50	10.15		CHEMBL
Histamine H1 receptor	GPCR		HRH1_CAVPO		Ki	9.07		CHEMBL
D(2) dopamine receptor	GPCR		DRD2_RAT		Ki	6.08		CHEMBL
Sodium-dependent serotonin transporter	Transporter		SC6A4_RAT		IC50	5.54		CHEMBL
5-hydroxytryptamine receptor 2A	GPCR		5HT2A_RAT		Ki	8.82		CHEMBL
Transporter	Transporter		Q9WTR4_RAT		Ki	7.59		CHEMBL
5-hydroxytryptamine receptor 7	GPCR		5HT7R_RAT		Ki	7.20		CHEMBL
5-hydroxytryptamine receptor 7	GPCR		5HT7R_MOUSE	ANTAGONIST	Ki	7		IUPHAR
D(1A) dopamine receptor	GPCR		DRD1_RAT		Ki	5.85		CHEMBL
5-hydroxytryptamine receptor 2C	GPCR		5HT2C_RAT		Ki	8.85		CHEMBL
Alpha-1A adrenergic receptor	GPCR		ADA1A_BOVIN		Ki	7.37		CHEMBL
D(3) dopamine receptor	GPCR		DRD3_RAT		Ki	5.82		CHEMBL
Alpha-2A adrenergic receptor	GPCR		ADA2A_BOVIN		Ki	7.77		CHEMBL
Muscarinic acetylcholine receptor M5	GPCR		ACM5_RAT		IC50	5.72		CHEMBL
5-hydroxytryptamine receptor 6	GPCR		5HT6R_RAT	ANTAGONIST	Ki	7.40		IUPHAR
Serotonin 3 (5-HT3) receptor	Ion channel		5HT3A_RAT 5HT3B_RAT		Ki	7.15		CHEMBL
Serotonin 1 (5-HT1) receptor	GPCR		5HT1A_RAT 5HT1B_RAT 5HT1D_RAT 5HT1F_RAT		Ki	6.24		CHEMBL
Adrenergic receptor alpha-2	GPCR		ADA2B_RAT ADA2C_RAT ADA2A_RAT		Ki	7.21		CHEMBL
Cerebral cortex alpha adrenergic receptor	GPCR		ADA1A_BOVIN ADA2A_BOVIN		IC50	8.22		CHEMBL
Serotonin 2 (5-HT2) receptor	GPCR		5HT2C_RAT 5HT2A_RAT 5HT2B_RAT		Ki	8.96		CHEMBL
Serotonin 3 receptor (5HT3)	Ion channel		5HT3A_MOUSE 5HT3B_MOUSE		Ki	6.60		CHEMBL
G-protein coupled receptor	GPCR		Q9NG02_APIME		IC50	4.14		CHEMBL
5-hydroxytryptamine receptor 1B	GPCR		5HT1B_MOUSE	ANTAGONIST	Ki	8.30		IUPHAR

External reference:

ID	Source
D01358	KEGG_DRUG
21535-47-7	SECONDARY_CAS_RN
4027429	VANDF
C0025912	UMLSCUI
CHEBI:51137	CHEBI
WRU	PDB_CHEM_ID
CHEMBL6437	ChEMBL_ID
CHEMBL544428	ChEMBL_ID
DB06148	DRUGBANK_ID
D008803	MESH_DESCRIPTOR_UI
4184	PUBCHEM_CID
135	IUPHAR_LIGAND_ID
2543	INN_ID
250PJI13LM	UNII
203127	RXNORM
18113	MMSL
004006	NDDF
004007	NDDF
387565003	SNOMEDCT_US
395795008	SNOMEDCT_US
96200003	SNOMEDCT_US
250PJI13LM	INXIGHT DRUGS

Pharmaceutical products:

None